

LA JOLLA PHARMACEUTICAL CO

Form 8-K

February 26, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): February 26, 2004

**LA JOLLA PHARMACEUTICAL COMPANY**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

---

0-24274

---

33-0361285

---

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive  
San Diego, California 92121  
(Address of Principal Executive Offices, Including Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

---

---

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On February 26, 2004, La Jolla Pharmaceutical Company issued a press release announcing that it had completed its previously announced public offering of 8,695,653 shares of common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Exhibits.**

(c) Exhibits:

The following exhibits are filed with this Report on Form 8-K:

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release, dated February 26, 2004

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 26, 2004

LA JOLLA PHARMACEUTICAL  
COMPANY

By: /s/ Steven B. Engle  
Steven B. Engle  
Chairman and Chief Executive Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release, dated February 26, 2004